follow strike data updat morn subsequ de-risk
kra inhibitor class increas price target
prior reiter overweight given similar mechan target bind
believ probabl produc similarli
impress dataset significantli increas result decreas discount
rate attach model result equiti valuat mirati interestingli
met manag afternoon follow data continu
high level convict could produc impress clinic
data base better xenograft data longer half-lif improv tissu distribut
think necessari reach price target believ signific
addit upsid would possibl scenario
look pretti darn good de-risk kra class drug
discuss earlier colleagu raymond team data
updat morn good could hope
orr lung hold sever patient experienc tumor reduct
appear close respond addit safeti profil appear except clean
three reason manag think could gener better clinic
data better xenograft data obviou caveat preclin data
manag note achiev complet respons therefor deeper
tumor reduct relev xenograft model rang dose
unabl longer half-lif therefor better target coverag disclos
morn hour half-lif combin once-daili dose
make unlik kra bound hour altern
hour half-lif allow better target coverag explain
lower synergi mek fact preclin develop manag intent
modifi extend half-lif reduc overreact manag also note
hyper-activ neg feedback loop could occur bind remov
improv tissu distribut preclin data caveat less
found circul drug appear enter tissu rel
initi data expect octob manag note on-going phase
dose escal studi progress similar fashion similar timelin
studi like receiv preclin clinic present
tripl meet octob given similar progress/timelin like receiv
data similar number patient updat morn data
posit manag note expans patient could like support
acceler approv first line trial would pursu page
clinic develop risk sitravatinib
mirati discov develop small molecul inhibitor treat cancer
price close june
dcf run account
us sale
us sale sitra combin nivo
debt total capit
piper jaffray seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis report read conjunct import disclosur inform
includ attest regul analyst certif found page report follow site
page
kra combin trial like start soon manag note intend start
trial combin agent second half year studi design
like sever differ arm combin egfr
palbociclib manag also believ combin excit given
rtk upregul gdp-base said combin would test
separ trial would involv two agent investig potenti novarti
nv uncov
valuat could conserv previous discuss decreas
discount rate dcf-base valuat result valuat
per share believ similar consider loxo receiv
acquisit lilli uncov earlier year despit fact number
lung cancer patient elig treatment inhibitor roughli higher
page
nsclc patient
lung adenocarcinoma patient
kra lung adenocarcinoma patient
identifi kra lung adenocarcinoma patient
patient
kra patient
identifi kra patient
pancreat cancer patient
kra pancreat cancer patient
identifi kra pancreat cancer patient
current disclosur inform compani locat http //www piperjaffray com/researchdisclosur
page
beigen asia
rcc hnscc
checkpoint-nav refractori nsclc rcc
checkpoint-nav refractori
checkpoint-nav gastric ovarian cancer
cbl-lof nsclc melanoma
nsclc pancreat cancer
nsclc pancreat
current disclosur inform compani locat http //www piperjaffray com/researchdisclosur
page
good sold
revenu
revenu
revenu
unreal gain loss invest
revenu
current disclosur inform compani locat http //www piperjaffray com/researchdisclosur
